DOSIsoft Launches DOSIsoft Theranostics, a Dedicated Entity to Accelerate Software Innovation for Personalized Nuclear Medicine and Theranostics
PARIS, May 26, 2026 /PRNewswire/ -- Ahead of SNMMI 2026, DOSIsoft, a leading…
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq:…
Integrating Immunology and Transplant Medicine on a Unified Platform: Manipal Hospital Yelahanka Hosts Landmark Immuno-Transplant Summit in Bengaluru
BENGALURU, India, May 8, 2026 /PRNewswire/ -- Marking a significant step in bridging…
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026 15:00 ET | Source: Roivant Sciences The results of…
Novartis IgAN data in New England Journal of Medicine show Fabhalta slowed kidney function decline by 49.3%
“Persistent kidney inflammation is a hallmark of IgAN, and a key driver…
Dupixent (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Approval in moderate-to-severe patients was based on pivotal trial results showing over…
Press Release: Sanofi and Regenerons Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine…
ACTG Announces Publication of LATITUDE Findings in the New England Journal of Medicine
Study Confirms Long-Acting Treatment is Effective among People Living with HIV Who…
Hassan Spine & Sports Medicine Rebrands as NefraHealth
New Identity Reflects Patient-First Philosophy, Practice Growth Board-Certified Spine Surgeon Joins Growing…
Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met…
